Research Papers:

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Xiaochuan Liu, Aoli Wang, Xiaofei Liang, Juanjuan Liu, Fengming Zou, Cheng Chen, Zheng Zhao, Yuanxin Deng, Hong Wu, Ziping Qi, Beilei Wang, Li Wang, Feiyang Liu, Yunhe Xu, Wenchao Wang, Stacey M. Fernandes, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, Teckpeng Loh, James D. Griffin, Shanchun Zhang, Ellen L. Weisberg _, Xin Zhang, Jing Liu and Qingsong Liu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:53515-53525. https://doi.org/10.18632/oncotarget.10650

Metrics: PDF 1799 views  |   HTML 2007 views  |   ?  


Xiaochuan Liu1,2,*, Aoli Wang2,3,*, Xiaofei Liang2,4,*, Juanjuan Liu2,3,*, Fengming Zou2,4,*, Cheng Chen2,4,*, Zheng Zhao2,4, Yuanxin Deng2,3, Hong Wu2,3, Ziping Qi2,4, Beilei Wang2,4, Li Wang2,4, Feiyang Liu2,3, Yunhe Xu1, Wenchao Wang2,4, Stacey M. Fernandes5, Richard M. Stone5, Ilene A. Galinsky5, Jennifer R. Brown5, Teckpeng Loh1, James. D. Griffin5, Shanchun Zhang4,6, Ellen L. Weisberg5, Xin Zhang2, Jing Liu2,4, Qingsong Liu2,3,7

1Department of Chemistry, University of Science and Technology of China, Anhui, Hefei, 230036, P. R. China

2High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, 230031, Anhui, P. R. China

3University of Science and Technology of China, Anhui, Hefei, 230036, P. R. China

4CHMFL-HCMTC Target Therapy Joint Laboratory, Hefei, 230031, Anhui, P. R. China

5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

6Hefei Cosource Medicine Technology Co. LTD. Hefei, 230031, Anhui, P.R.China

7Hefei Science Center, Chinese Academy of Sciences, Hefei, 230031, Anhui, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Ellen L. Weisberg, email: Ellen_weisberg@dfci.harvard.edu

Xin Zhang, email: xinzhang@hmfl.ac.cn

Jing Liu, email: jingliu@hmfl.ac.cn

Qingsong Liu, email: qsliu97@hmfl.ac.cn

Keywords: PI3Kδ, Vps34, combination, chronic lymphatic leukemia, acute myeloid leukemia

Received: April 19, 2016     Accepted: June 03, 2016     Published: July 18, 2016


PI3Kδ has been found to be over-expressed in B-Cell-related malignancies. Despite the clinical success of the first selective PI3Kδ inhibitor, CAL-101, inhibition of PI3Kδ itself did not show too much cytotoxic efficacy against cancer cells. One possible reason is that PI3Kδ inhibition induced autophagy that protects the cells from death. Since class III PI3K isoform PIK3C3/Vps34 participates in autophagy initiation and progression, we predicted that a PI3Kδ and Vps34 dual inhibitor might improve the anti-proliferative activity observed for PI3Kδ-targeted inhibitors. We discovered a highly potent ATP-competitive PI3Kδ/Vps34 dual inhibitor, PI3KD/V-IN-01, which displayed 10-1500 fold selectivity over other PI3K isoforms and did not inhibit any other kinases in the kinome. In cells, PI3KD/V-IN-01 showed 30-300 fold selectivity between PI3Kδ and other class I PI3K isoforms. PI3KD/V-IN-01 exhibited better anti-proliferative activity against AML, CLL and Burkitt lymphoma cell lines than known selective PI3Kδ and Vps34 inhibitors. Interestingly, we observed FLT3-ITD AML cells are more sensitive to PI3KD/V-IN-01 than the FLT3 wt expressing cells. In AML cell inoculated xenograft mouse model, PI3KD/V-IN-01 exhibited dose-dependent anti-tumor growth efficacies. These results suggest that dual inhibition of PI3Kδ and Vps34 might be a useful approach to improve the PI3Kδ inhibitor’s anti-tumor efficacy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10650